See the DrugPatentWatch profile for Toviaz
The generic version of Toviaz, which is extended-release fesoterodine fumarate, is not yet available in the United States [1]. Currently, only the brand-name Toviaz is approved [1].
When might a generic version of Toviaz become available?
The availability of a generic version of Toviaz depends on patent expirations and any potential patent litigation. DrugPatentWatch.com tracks patent information for medications and may provide details on the patent status of Toviaz [2]. Generally, once patents expire and no other exclusivity rights are in place, generic manufacturers can seek approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) to market their versions [3].
What is Toviaz used for?
Toviaz is a medication used to treat overactive bladder (OOB) with symptoms of urge urinary incontinence, urinary urgency, and urinary frequency [4]. It belongs to a class of drugs called antimuscarinics [4].
How does fesoterodine fumarate work?
Fesoterodine fumarate works by blocking the action of acetylcholine on bladder muscles. Acetylcholine is a chemical messenger that can cause bladder muscles to contract, leading to the symptoms of an overactive bladder. By blocking acetylcholine, fesoterodine fumarate helps to relax the bladder muscles, reducing involuntary contractions and alleviating symptoms like urinary urgency and incontinence [4].
Are there other treatments for overactive bladder?
Yes, there are several other treatment options for overactive bladder, including behavioral therapies, other medications, and in some cases, medical devices or surgery [5]. These alternatives may differ in their mechanisms of action, side effect profiles, and efficacy [5].
What are the potential side effects of Toviaz?
Common side effects of Toviaz can include dry mouth, constipation, and impaired vision (difficulty focusing) [4]. Less common but more serious side effects may also occur [4]. Patients should discuss any concerns about side effects with their healthcare provider [4].
---
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?fuseAction=overview.returnPage&productid=251030
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/development-approval-process-drugs/overview-drug-development-approval-process
[4] https://www.toviaz.com/
[5] https://www.mayoclinic.org/diseases-conditions/overactive-bladder/diagnosis-treatment/drc-20354204